Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s

Full Data Presented At CTAD Congress

 
• By Andrew McConaghie
  
Roche_Basel
Roche's 'brain shuttle' technology is a promising 'next gen' technology, but for now has missed out while Eisai and Biogen head to market • Source: Image archive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip